Fusion protein · Protein replacement: transferrin receptor (TFRC) · developed by Denali Therapeutics
Tividenofusp alfa is a fusion protein that supplies iduronate-2-sulfatase (IDS), a lysosomal enzyme, fused to an Fc component that binds the transferrin receptor to carry the enzyme across the blood-brain barrier and into peripheral tissues and the CNS. It is studied in mucopolysaccharidosis II (Hunter syndrome).
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05371613 | Phase 2/3 | Mucopolysaccharidosis II | Active not recruiting | DNLI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mucopolysaccharidosis II
Updated Oct 11, 2026. Something wrong or missing? Report it on the DNLI page.
See DNLI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
DNLI catalysts and pipeline →